Having trouble accessing articles? Reset your cache.

MGCD265: Updated Phase II data

MethylGene reported updated preliminary data from the ongoing, 2-part, open-label, dose-escalation Phase II Trial 103 trial evaluating once-daily oral MGCD256 for 21 days in combination with either Tarceva erlotinib or

Read the full 301 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE